Every Form 4 that Legend Biotech Corporation (LEGN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow LEGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LEGN filings page.
Legend Biotech Corp (LEGN) reported that Interim CEO Alan Bash received a grant of 4,908 restricted share units (RSUs) on August 14, 2026. These RSUs convert into ordinary shares on settlement, increasing his direct holdings to 35,142 ordinary shares. The RSUs vest in three equal annual installments on July 27, 2027, 2028, and 2029, subject to continued service. Each ordinary share may also be represented by American Depositary Shares, with one ADS equal to two ordinary shares.
Legend Biotech Corp director Casey Patrick John sold 6,000 Ordinary Shares in an open-market transaction. The sale took place at $14.80 per ordinary share, equivalent to $29.60 per American Depositary Share, with each ADS representing two ordinary shares. After this trade, he directly holds 48,604 Ordinary Shares, indicating he retains a substantial ongoing equity position in the company.
Legend Biotech Corp director and CEO Ying Huang reported a charitable stock gift. On this Form 4, Huang made a bona fide gift transfer of 3,382 Ordinary Shares of Legend Biotech Corp to a charitable organization, receiving no cash consideration.
After the gift, Huang directly owns 238,490 Ordinary Shares. The company notes that its Ordinary Shares may be represented by American Depositary Shares, with each ADS representing two Ordinary Shares.
Legend Biotech Corp Chief Executive Officer Ying Huang reported a disposition of ordinary shares tied to equity compensation taxes. On June 25, 2026, 5,566 ordinary shares were sold at a weighted average price of $14.78 per share, based on converted ADS prices.
According to the disclosure, these shares were sold to satisfy withholding tax obligations upon the vesting of restricted share units, making this a compensation-related, non-discretionary event rather than a typical open-market sale. Following the transaction, Huang directly holds 241,872 ordinary shares of Legend Biotech.
Legend Biotech Corp Chief Executive Officer Ying Huang reported the sale of 9,936 ordinary shares on March 25, 2026. The weighted average price was $8.77 per ordinary share. According to the disclosure, these shares were sold to satisfy withholding tax obligations upon the vesting of restricted share units. Following this transaction, Huang directly holds 247,438 ordinary shares.